Organon & Co
Prezzo: 13.44Società e modello di business
Organon & Co is a global healthcare company focused on women's health, biosimilars, and established medicines. Its core products include contraceptives, hormone therapies, and treatments for various chronic conditions. The company operates primarily in women's health and biosimilars, with major revenue sources stemming from its portfolio of prescription medications and healthcare solutions. Organon aims to address unmet medical needs and improve health outcomes for women.
Profilo di investimento
The investment profile of Organon & Co is more aligned with balanced investors, given its modest dividend yield and stable revenue streams. The company has shown some volatility and a recent decline in revenue, which may appeal to those seeking a mix of growth and income. The stock's characteristics suggest it may be suitable for investors looking for moderate risk and potential for steady returns over time.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 0.95 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -3.1% ↓
- Sorpresa EPS
- -14.5% peggio del previsto
- Volatilità 20g
- 0.2% stabile
- Rendimento dividendo
- 0.6% basso ultima data ex-dividendo: 2026-05-11
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-13 02:43 | Mantieni | Vendi | Weak fundamentals and mixed momentum signal caution. |
| 2026-06-05 02:45 | Vendi | Mantieni | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-28 02:54 | Mantieni | Vendi | Weak fundamentals and negative momentum raise concerns. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-04-27 20:27 | Piper Sandler | Rating migliorato | — → 14 | 13.175 |
| 2026-04-10 15:02 | BNP Paribas | Aggiorna | — → 12 | 8.685 |
| 2026-02-24 10:45 | Barclays | Target alzato | 7.5 → 8 | 7.92 |
Ancora nulla